The different barriers that slow the penetration of active ingredients administered by the ocular route are described, and some novel dosage forms designed for this route are discussed. Both precorneal and corneal factors considerably restrict ocular penetration. The low bioavailability of classical ophthalmic dosage forms can be improved by several approaches, particularly by increasing the time the active ingredients remain in contact with the eye tissues.
The new dosage forms are reviewed according to their type and their drug release mechanisms. The characteristics, advantages, and limitations of each are outlined. The potential of these dosage forms can be expected to enhance development. They offer prolonged effectiveness, reproducibility, fewer unwanted side effects, and improved tolerance.
1. Robinson, J. R.1980. Ophthalmic Drug Delivery Systems. Edition American Pharmaceutical Association (APhA).
2.
2. Jarvinen, F., T. Jarvinen and A. Urtti. 1995. "Ocular Absorption Following Topical Delivery,"Adv. Drug Delivery Rev., 16(1):3-19.
3.
3. Lee, V. HL. and J. R. Robinson. 1979. "Mechanistic and Quantitative of Pilocarpine Disposition in Albinos Rabbits,"J Pharm. Sci., 68:673-684.
4.
4. Bodor, N.1995. "Retrometabolic Drug Design Concepts in Ophthalmic Target-Specific Drug Delivery,"Adv. Drug Delivery Rev., 16(1):21-38.
5.
5. Saettone, M. F., P. Chetoni, R. Cerbai and G. Mazzanti. 1994. "Effect of Different Enhancers on in vitro Transcorneal Penetration of Drugs,"Proceed. Inter Symp. Contro. Rel. Bioact. Mater, 21:591-592.
6.
6. Visor, G. C.1994. "Drug Design for Ocular Therapeutics,"Adv. Drug Delivery Rev., 14(2/3):269-279.
7.
7. Prokai, L. and N. Bodor. 1995. "Ocular Delivery of the Beta-Adrenergic Antagonist Alprenolol by Sequential Bioactivation of its Methoxime Analogue,"J. Med. Chem., 38(11):2018-2020.
8.
8. Frangie, J. P.1995. "Clinical Pharmacokinetics of Various Topical Ophthalmic Delivery Systems,"Clin. Pharmacokinet., 29(2):130-138.
9.
9. Greaves, G. L., O. Olejnic and C. G. Wilson. 1992. "Polymers and the Precorneal Tear Film;"STP Pharma Sciences, 2(1):13-33.
10.
10. Greaves, G. L. and C. G. Wilson. 1993. "Treatment of Diseases of the Eye with Mucoadhesive Delivery Systems,"Advanced Drug Delivery Rev., 11:349-383.
11.
11. Hoffman, A. S., G. Chen, S. Kaang and D. T. Priebe. 1995. "New Bioadhesive Polymer Compositions for Prolonged Drug Release in the Eye,"Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 22, Controlled Release Society, Inc..
12.
12. Schoenwald, R. D.1990. "Ocular Drug Delivery. Pharmacokinetic Considerations,"Clin. Pharmacokinet., 18(4):155-269.
13.
13. Rigal, D. 1993. L'Epithelium Corneen. Societe Franqaise d'Ophtalmologie, Masson Edition, pp. 391-415.
14.
14. Sole, P., H. Dalens and G. Gentou. 1992. Biophtalmologie. Societe Franqaise d'Ophtalmologie, Masson Edition.
15.
15. Grass, G. M. and J. R. Robinson. 1983. "Mechanism of Corneal Permeation and Drug Penetration, in vivo and in vitro Kinetics,"J Pharma. Sci., 1:3-14.
16.
16. Romanelli, L., P Valeri, A. Morronel, G. Pimpinella, G. Graziani and B. Tita. 1994. "Ocular Absorption and Distribution of Bendazac after Topical Administration to Rabbits with Different Vehicles,"Life Sciences, 54(13):877-885.
17.
17. Hume, L. R., H. K. Lee, L. Benedetti, U. D. Sanzgiri, E. M. Topp and V. J. Stella. 1994. "Ocular Sustained Delivery of Prednisolone Using Hyaluronic Acid Benzyl Ester Films,"Int. J. Pharmaceutics, 111:295-298.
18.
18. Saettone, M. F. and L. Salimen. 1995. "Ocular Inserts for Topical Delivery,'Adu. Drug Delivery Rev., 16:95-106.
19.
19. Gurny, R., H. Ibrahim, A. Aebi, P. Buri, G. G. Willson and N. Washington. 1987. "Design and Evaluation of Controlled Release Systems for the Eye,"JI Controlled Release, 6:367-373.
20.
20. Le Bourlais, C. A., L. Treupel-Acar, C-T. Rhodes, P-A. Sado and R. Laverge. 1995. "New Ophthalmic Drug Delivery Systems,"Drug Development and Industrial Pharmacy, 21(1):19-59.
21.
21. Rozier, A. and B. Plazonnet. 1987. "Systemes Matriciels Ocularies: Exemples et Problemes Specifiques,"S.TP Pharma., 3(4):332-334.
22.
22. Rozier, A., C. Mazier, J. Grove and B. Plazonnet. 1989. "Gelrite®: A Novel, Ion Activated, in situ Gelling Polymer for Ophthalmic Vehicles. Effect on Bioavailability of Timolol,"Int. J Pharm., 57:163-168.
23.
23. Uppal, P., H. D. Jampel, H. A. Quigley and K. W. Leong. 1994. "Pharmacokinetics of Etoposide by a Bioerodible Drug Carrier Implanted at Glaucoma Surgery,"J. Ocul. Pharmacol., 10(2):471-479.
24.
24. Kunou, N., Y. Ogura, M. Hashiozoe, Y. Honda, S. H. Hyon and Y. Ikada. 1995. "Controlled Intraocular Delivery of Ganciclovir with Use of Biodegradable Scleral Implant in Rabbits,"J Controlled Release, 37:143-150.
25.
25. Deschpande, S. G. and S. Rathod. 1995. "Pilocarpine Bioavailability from Microspheres Ophthalmic Drug Delivery System,"Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 22, Controlled Release Society, Inc..
26.
26. Durrani, A. M., S. J. Farr and I. W. Kellaway. 1995. "Precorneal Clearance of Mucoadhesive Microspheres from the Rabbit Eye,"J. Pharm. Pharmacol., 47:581-584.
27.
27. Buri, P., F. Puisieux, E. Doelker and J-P. Benoit. 1985. "Voie Oculaire,"Formes Pharmaceutiques Nouvelles,Lavoisier, Paris.
28.
28. Meisner, D. and M. Mezei. 1995. "Liposome Ocular Delivery Systems,"Adv. Drug Delivery Rev., 16(1):75-93.
29.
29. Kreuter, J., R. Diepold and G. Andermann. 1988. "Comparison of Different in vitro and in vivo Test Models for Pilocarpine Using Conventional and Depot Eye Drops (Nanoparticles),"Proceed. Inter Sym. Control. Rel. Bioact. Mater, 15, Controlled Release Society, Inc.: pp. 203-204.
30.
30. Maincent, P., L. Marchal-Heussler, P Thouvenot, D. Sirbat, M. Hoffman, J. A. Vallet and M. Bergamini. 1995. "Ocular Distribution of Indium Oxime Following Tbpical Administration of Poly(Epsilon Caprolactone) Nanocapsules,"Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 22, Controlled Release Society, Inc..
31.
31. Rollot, J. M., P Couvreur, L. Roblot-Treupel, J. P. Devissaguet and F. Puisieux. 1986. "Physico-Chemical and Morphological Characterization of Polyisobutylcyanoacrylate Nanocapsules,"J Pharm. Sci., 75:361-364.
32.
32. Alonso, M. J., P. Calvo, J. L. Vila-Jato, M. I. Lopez, J. Liorente and J. C. Pastor. 1995. "Increased Ocular Corneal Uptake of Drugs Using Poly-Epsilon-Caprolactone Nanocapsules and Nanoemulsions,"Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 22 Controlled Release Society, Inc..
33.
33. Zimmer, A. and J. Kreuter. 1995. "Microspheres and Nanoparticles Used in Ocular Delivery Systems,"Adv. Drug Delivery Rev., 16(1):61-73.
34.
34. Joshi, A.1994. "Microparticles for Ophthalmic Drug Delivery,"J. Ocul. Pharmacol., 10(1):29-45.
35.
35. Robinson, J. R. and G. M. Mlynek. 1995. "Bioadhesive and Phase-Change Polymers for Ocular Drug,"Adu Drug Delivery Rev., 16(1):45-50.
36.
36. Sturesson, C., J. Carlfors and A. C. Albertsson. 1995. "Poly(Adipic Anhydride) Microspheres for Ocular Drug Delivery,"Proceed Intern. Symp. Control. Rel. Bioact. Mater, 22:756-757Controlled Release Society, Inc..
37.
37. Zimmer, A., E. Mutschler, G. Lambrecht, D. Mayer and J. Kreuter. 1994. "Pharmacokinetic and Pharmacodynamic Aspects of an Ophthalmic Pilocarpine Nanoparticle-Delivery System,"Pharmaceutical Research, 11(10):1435-1442.
38.
38. Zimmer, A., E. Mutschler, G. Lambrecht, D. Mayer and J. Kreuter. 1994. Pharmacopee Europeenne Inserts Ophtalmiques "Inserenda Ophtalmica," Janvier, 2 eme Edition.
39.
39. Gurtler, F. and R. Gurny. 1995. "Patent Literature Review of Ophthalmic Insert,"Drug Development and Industrial Pharmacy, 21(1):1-18.
40.
40. Heilmann, K."Rate-Controlled Drug Delivery: Concept and Development, 2nd Revised Edition, Therapeutic Systems.
41.
41. Daragour, S. 1992. U.S. Patent 5,147,647.
42.
42. Sasaki, H., C. Tei, K. Knishida and J. Jnakamura. 1993. "Drug Release from an Ophthalmic Insert of a Beta-Blocker as an Ocular Drug Delivery System,"J Controlled Release, 27:127-137.
43.
43. Aiache, J. M. and G. Serpin. 1993. Europeen Patent Appl. No. 910.086-3.
44.
44. Scrip Reports. 1994. "Ophthalmic Drug Delivery Systems;" in Drug Delivery Systems, Chapter 6. PJB Publications Ltd..
45.
45. Vairon, J. P., L. Yean, J. C. Meslard, R Subira and C. Bunel. 1992. "Immobilisation Reversible sur Polymeres et Liberation Controlee. Application Aux Lentilles Corneennes Reservoirs de Medicaments," LActualite Chimique, Septembre-Octobre.
46.
46. Kaufman, H. E., T. L. Steinemann, E. Lehman, H. W. Thompson, E. D. Varnell and J. Labarre. 1994. "Collagen-Based Drug Delivery and Artificial Tears,"J. Ocul. Pharmacol., 10(1)17-27.
47.
47. Middelton, D. L. and J. R. Robinson. 1991. "Design and Evaluation of an Ocular Bioadhesive Delivery System,"STP Pharma. Sciences, 1(3):200-206.
48.
48. El-Faham, T. H. and A. A. Massoud. 1994. "Assessment of Bromohexine Hydrochloride Formulations in Human Dry Eye Patients,"J. Controlled Release, 32:279-283.
49.
49. El-Shanawany, S."Ocular Delivery of Pilocarpine from Ocular Inserts,"STP Pharma. Sciences, 2(4):337-341.
50.
50. Gurtler, F., B. Boisrame, V. Kaltsatos and R. Gurny. 1993. "Bioadhesive Ophthalmic Drug Inserts (BODI) Containing Gentamicin,"Fifth European Congress of Biopharmaceutics and Pharmacokinetics, Brussels, April 20-22.
51.
51. Saettone, M. E., M. T. Torracca, A. Pagano, B. Giannaccini, L. Rodriguez and M. Cini. 1992. "Controlled Release of Pilocarpine from Coated Polymeric Ophthalmic Inserts Prepared by Extrusion,"Int. J. Pharmaceutics, 86:159-166.
52.
52. Saettone, M. F., P Chetoni, M. T. Torracca, B. Giannaccini, L. Naber, U. Conte, M. E. Sangalli and A. Gazzaniga. 1990. "Application of the Compression Technique to the Manufacture of Pilocarpine Ophthalmic Inserts,"Acta Pharm. Technol., 36(1):15-19.
53.
53. Dumortier, G., M. Zuber and J. C. Chaumeil. 1989. "Les Inserts Ophtalmiques Solubles ou Bioerodables: Caracteres Generaux, Formulations, Evaluation in vitro Puis in vivo," STP Pharma., 5(8/9):561-566.
54.
54. Lawrenson, J. G., D. F. Edgar, N. Gudgeo, J. M. Burns, M. Geraint and N-A. Barnard. 1993. "A Comparison of the Efficacy and Duration of Action of Topically Applied Proxymetacaine Using a Novel Ophthalmic Delivery System Versus Eye Drops in Healthy Young Volunteers,"Br J Ophthalmology, 77:713-715.
55.
55. Greaves, J. L., C. G. Wilson, A. T. Birmingham, M. C. Richardson and P H. Bentley. 1992. "Scintigraphic Studies on the Corneal Residence of a New Ophthalmic Delivery System (NODS): Rate of Clearance of Soluble Marker in Relation to Duration of Pharmacological Action of Pilocarpine,"Br J. Clin. Pharmac, 33:603-609.
56.
56. Gurtler, F., V. Kaltsatos, B. Boisrame and R. Gurny. 1995. "Long-Acting Soluble Bioadhesive Drug Insert (BODI) Containing Gentamicin for Veterinary Use: Optimisation and Clinical Investigation,"J. Controlled Release, 33:231-236.
57.
57. Merkli, A., J. Heller, C. Tabataby and R. Gurny. 1994. "Semi-Solid Hydrophobic Bioerodible Poly (Ortho Ester) Potential Application in Glaucoma Filtering Surgery,"J Controlled Release, 29:105-112.
58.
58. Merkli, A., C. Tabataby and R. Gurny. 1995. "Use of Insoluble Biodegradable Polymers in Ophthalmic Systems for the Sustained Release of Drugs,"Eur J. Pharm. Biopharm., 41(5):271-283, Adv.
